Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 776 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infections, Gram-Positive Bacterial Clear all
Completed Phase 1 Interventional

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

NCT00136292
View directory record Official record
Conditions
Gram-positive Bacterial Infections
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Kansas City, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
View directory record Official record
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

NCT00000950
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

NCT04922554
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Omadacycline Oral Tablet, Placebo
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

NCT00002122
View directory record Official record
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay

NCT07220031
View directory record Official record
Conditions
Osmolality Disturbance, Lab Interference
Interventions
Activated Charcoal
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Livestock Contact and MRSA in Rural Areas

NCT01375621
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Months to 100 Years
Enrollment
1,342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Coralville, Iowa
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

NCT03275870
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Elena Gonzalez Brant, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

NCT01768273
View directory record Official record
Conditions
Tuberculosis
Interventions
Midazolam, PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

NCT00001039
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Tucson, Arizona • Baltimore, Maryland • Camden, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

NCT02024867
View directory record Official record
Conditions
Skin Disease, Bacterial, Abscess
Interventions
Trimethoprim-Sulfamethoxazole
Drug
Lead sponsor
Lucy Holmes, MD
Other
Eligibility
3 Months to 17 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

NCT04258995
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 51 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
4
States / cities
Stockbridge, Georgia • Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management

NCT05772065
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
CDC/NTCA guidelines only, LTBI ASSIST and CDC/NTCA guidelines only
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational

Immune Response to Mycobacterium Tuberculosis Infection

NCT00257907
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

NCT06112834
View directory record Official record
Conditions
Botulism
Interventions
rBV A/B
Biological
Lead sponsor
California Department of Public Health
Other
Eligibility
18 Years to 69 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Richmond, California • West Jefferson, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the QuantiFERON-TB Test.

NCT02256839
View directory record Official record
Conditions
Tuberculosis
Interventions
CST_001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

NCT00001911
View directory record Official record
Conditions
Atypical Mycobacterium Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Pneumonia Vaccine Education Intervention Study

NCT06136832
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccine
Interventions
Pneumococcal Vaccine Education
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed No phase listed Observational Results available

Evaluation of the QuantiFERON-TB Test.

NCT02253537
View directory record Official record
Conditions
Tuberculosis
Interventions
CST001
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

NCT03603665
View directory record Official record
Conditions
Botulism
Interventions
NTM-1633, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 4 Interventional

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
Drug · Other · Radiation
Lead sponsor
University of Melbourne
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 5:02 PM EDT